Ikena Oncology Inc. (IKNA)
1.51
-0.03 (-1.95%)
At close: Jan 14, 2025, 3:59 PM
1.51
0.00%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 1.5 |
| Market Cap | 60.79M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.21 |
| PE Ratio (ttm) | -1.25 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.74 |
| Volume | 112,227 |
| Avg. Volume (20D) | 195,940 |
| Open | 1.53 |
| Previous Close | 1.54 |
| Day's Range | 1.46 - 1.56 |
| 52-Week Range | 1.22 - 1.94 |
| Beta | undefined |
About IKNA
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-1...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 26, 2021
Employees 14
Stock Exchange NASDAQ
Ticker Symbol IKNA
Website https://ikenaoncology.com
Analyst Forecast
According to 2 analyst ratings, the average rating for IKNA stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 98.68% from the latest price.
Buy 50.00%
Hold 50.00%
Sell 0.00%
Next Earnings Release
Ikena Oncology Inc. is scheduled to release its earnings on Mar 11, 2025,
before market opens.
Analysts project revenue of $1.67M, reflecting a 153.80% YoY growth and earnings per share of -0.23, making a -43.90% decrease YoY.
Analysts project revenue of $1.67M, reflecting a 153.80% YoY growth and earnings per share of -0.23, making a -43.90% decrease YoY.
7 months ago ·
Source
+25.56%
Ikena Oncology shares are trading higher after the...
Unlock content with
Pro Subscription
7 months ago ·
Source
Ikena Oncology shares are trading higher after the company announced it will discontinue development of IK-930 and evaluate strategic options for both the Company and its development pipeline.
